Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

AtorvaStatin Postpartum and Reduction of Cardiovascular risK — Stella

Home/Hypertensive Disorders of Pregnancy/AtorvaStatin Postpartum and Reduction of Cardiovascular risK

View on ClinicalTrials.gov

Recruiting

Back to Hypertensive Disorders of Pregnancy trials

AtorvaStatin Postpartum and Reduction of Cardiovascular risK

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(1 site)

United States

The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine, Columbus, Ohio

Key details

Phase

Post-approval study

Sponsor

Ohio State University

Enrollment target

~76 participants

Started

October 2025

Primary completion

September 2026

Age range

20 Years – 50 Years

Sex

Female only

Last updated October 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.